Drug Profile


Alternative Names: Antril; Kineret; Recombinant human interleukin-1 receptor antagonist; rhIL-1ra

Latest Information Update: 18 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Swedish Orphan Biovitrum
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes; Juvenile rheumatoid arthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
  • Phase III Adult-onset Still's disease; Juvenile rheumatoid arthritis
  • Phase II Gout
  • Discontinued Ankylosing spondylitis; Graft-versus-host disease; Osteoarthritis; Pneumococcal infections; Septic shock

Most Recent Events

  • 26 Sep 2017 Phase-III clinical trials in Adult-onset Still's disease in USA (SC) (NCT03265132)
  • 26 Sep 2017 Phase-III clinical trials in Juvenile rheumatoid arthritis in USA (SC) (NCT03265132)
  • 31 Aug 2017 Shenzhen BinDeBio plans the phase III anaSTILLs trial for Juvenile rheumatoid arthritis (SC) (NCT03265132)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top